C4 Therapeutics, Inc. CCCC

US Biotechnology

$3.02 ▼ -4.13% ($-0.13)

⬇️ Below Yest. Low 🔥 High Short Interest 🎢 High Beta

Open $3.13

Prev Close $3.15

Day Range $2.93 – $3.16

52W Range $1.69 – $5.17

Market Cap $413.65M

Beta 3.23

EPS (TTM) $-1.00

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-10-02
Shares Out.	123,030,000
Website	c4therapeutics.com/ ↗
Phone	13026587581
Employees	104
Revenue	$8.5M
Gross Profit	$8.5M
Net Income	-$21.8M
Free Cash Flow	-$79.7M
Total Assets	$331.8M
Total Liabilities	$103.6M
Equity	$228.2M

About C4 Therapeutics, Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

C4 Therapeutics, Inc. is a publicly traded company under the ticker symbol CCCC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.